Active Ingredient(s): Eliglustat
FDA Approved: * August 19, 2014
Pharm Company: * GENZYME CORP
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Cerdelga Overview

Eliglustat (INN, USAN;[1] trade name Cerdelga) is a treatment for Gaucher's disease discovered at the University of Michigan and developed by Genzyme Corp that was approved by the FDA August 2014.[2] Commonly used as the tartrate salt, the compound is believed to work by inhibition of glucosylceramide synthase.[3][4] According to an article in Journal of the American Medical Association the oral substrate reduction therapy result...

Read more Cerdelga Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eliglustat

Recent Cerdelga Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 84 Mg., 84mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cerdelga: (1 result)

Sorted by National Drug Code
  • 58468-0220 Cerdelga 84 mg Oral Capsule by Genzyme Corporation

Other drugs which contain Eliglustat or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 3 August 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA